SPY317.59+3.21 1.02%
DIA260.82+3.58 1.39%
IXIC10,617.44+69.69 0.66%

Stifel Initiates Coverage On Calliditas Therapeutics with Buy Rating, Announces Price Target of $28

Stifel analyst Annabel Samimy initiates coverage on Calliditas Therapeutics (NASDAQ:CALT) with a Buy rating and announces Price Target of $28.

Benzinga · -
Stifel analyst Annabel Samimy initiates coverage on Calliditas Therapeutics (NASDAQ: CALT) with a Buy rating and announces Price Target of $28.